PubRank
Search
About
Norma Peter
Author PubWeight™ 24.47
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Lancet Oncol
2008
5.50
2
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
Blood
2007
5.18
3
Improvement of overall survival in advanced stage mantle cell lymphoma.
J Clin Oncol
2008
3.44
4
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Blood
2011
2.37
5
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Blood
2010
1.94
6
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
Lancet Oncol
2012
1.86
7
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.
Blood
2012
1.58
8
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
Haematologica
2013
1.19
9
Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.
Ann Hematol
2005
0.82
10
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
Br J Haematol
2014
0.80
11
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone).
Ann Hematol
2008
0.76